Physician profile
Mark H Cooper
NPI 1346376613
$218,598.36
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $70K · 2021: $34K · 2022: $40K · 2023: $1,340 · 2024: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,151 · Food and Beverage: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,151.15 |
| Food and Beverage | $746.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $213,906.48 | 2019-2022 | |
| Intuitive Surgical, INC. | $1,477.75 | 2019-2024 | Da Vinci Surgical System |
| Enterra Medical, INC. | $1,210.57 | 2024 | |
| Covidien LP | $626.81 | 2019-2020 | |
| Novocure INC. | $297.82 | 2021-2022 | |
| Ethicon INC. | $213.55 | 2022 | |
| Zimmer Biomet Holdings, INC. | $175.24 | 2019-2020 | |
| Medtronic, INC. | $164.05 | 2021-2023 | Illumisite |
| Atricure, INC. | $159.73 | 2019 | |
| Bard Access Systems, INC. | $118.91 | 2019 | |
| Allergan, INC. | $92.18 | 2022 | |
| Pulmonx Corporation | $43.56 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Ethicon US, LLC | $35.92 | 2019 | |
| Merck Sharp & Dohme LLC | $32.53 | 2024 | Keytruda |
| Novo Nordisk INC | $15.26 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14.80 | 2023 | Tecentriq |
| Kci USA, INC. | $13.20 | 2023 | Prevena, V.A.C. Dermatac, V.A.C. Veraflo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.